Benzyl tetrahydrothiophene-2-carboxylate 1,1-dioxide | 327618-07-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Benzyl tetrahydrothiophene-2-carboxylate 1,1-dioxide
• 英文别名: benzyl 1,1-dioxothiolane-2-carboxylate
• CAS: 327618-07-5
• 化学式: C₁₂H₁₄O₄S
• 分子量: 254.307
• InChiKey: MZLBGOQATXEFDO-UHFFFAOYSA-N

物化性质

• 沸点：
  443.6±38.0 °C(Predicted)
• 密度：
  1.313±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  68.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Benzyl tetrahydrothiophene-2-carboxylate 1,1-dioxide 在 palladium on activated charcoal benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 氢气 、 N,N-二异丙基乙胺 、 三氟乙酸 、 lithium hexamethyldisilazane 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 生成 (S)-3-(2''-Methoxy-biphenyl-4-yl)-2-[(2-methyl-tetrahydro-furan-2-carbonyl)-amino]-propionic acid
  参考文献：
  名称：

  N-Tetrahydrofuroyl-(l)-phenylalanine derivatives as potent VLA-4 antagonists

  摘要：

  Given the proposed involvement of VLA-4 in inflammatory processes, a program to identify orally active VLA-4 antagonists was initiated. Herein, we report the discovery of a N-tetrahydrofuroyl-(L)-phenylalanine derivative (17) and related analogues as potent VLA-4 antagonists with good oral bioavailability. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00210-x
• 作为产物：
  描述：

  环丁砜 、 氯甲酸苄酯 在 lithium hexamethyldisilazane 作用下， 以64%的产率得到Benzyl tetrahydrothiophene-2-carboxylate 1,1-dioxide
  参考文献：
  名称：

  N-Tetrahydrofuroyl-(l)-phenylalanine derivatives as potent VLA-4 antagonists

  摘要：

  Given the proposed involvement of VLA-4 in inflammatory processes, a program to identify orally active VLA-4 antagonists was initiated. Herein, we report the discovery of a N-tetrahydrofuroyl-(L)-phenylalanine derivative (17) and related analogues as potent VLA-4 antagonists with good oral bioavailability. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00210-x

文献信息

• [EN] HETEROCYCLE AMIDES AS CELL ADHESION INHIBITORS<br/>[FR] AMIDES HETEROCYCLES COMME INHIBITEURS DE L'ADHESION CELLULAIRE
  申请人：MERCK & CO INC

  公开号：WO2001012183A1

  公开（公告）日：2001-02-22

  Compounds of Formula (I) are antagonists of VLA-4 and/or α4β7, and as such are useful in the inhibition or prevention of cell adhesion and cell-adhesion mediated pathologies. These compounds may be formulated into pharmaceutical compositions and are suitable for use in the treatment of AIDS-related dementia, allergic conjunctivitis, allergic rhinitis, Alzheimer's disease, asthma, atherosclerosis, autologous bone marrow transplantation, certain types of toxic and immune-based nephritis, contact dermal hypersensitivity, inflammatory bowel disease including ulcerative colitis and Crohn's disease, inflammatory lung diseases, inflammatory sequelae of viral infections, meningitis, multiple sclerosis, multiple myeloma, myocarditis, organ transplantation, psoriasis, pulmonary fibrosis, restenosis, retinitis, rheumatoid arthritis, septic arthritis, stroke, tumor metastasis, uveititis, and type I diabetes.

  化合物I的配合物是VLA-4和/或α4β7的拮抗剂，因此可用于抑制或预防细胞粘附和细胞粘附介导的病理反应。这些化合物可以制成药物组合物，适用于治疗艾滋病相关痴呆症、过敏性结膜炎、过敏性鼻炎、阿尔茨海默病、哮喘、动脉粥样硬化、自体骨髓移植、某些类型的毒性和免疫性肾炎、接触性皮肤过敏、炎症性肠病（包括溃疡性结肠炎和克罗恩病）、炎症性肺部疾病、病毒感染后的炎症后遗症、脑膜炎、多发性硬化症、多发性骨髓瘤、心肌炎、器官移植、银屑病、肺纤维化、再狭窄、视网膜炎、类风湿性关节炎、脓毒性关节炎、中风、肿瘤转移、葡萄膜炎和1型糖尿病的治疗。
• US6420418B1
  申请人：——

  公开号：US6420418B1

  公开（公告）日：2002-07-16
• N-Tetrahydrofuroyl-(l)-phenylalanine derivatives as potent VLA-4 antagonists
  作者：Ginger X. Yang、Linda L. Chang、Quang Truong、George A. Doherty、Plato A. Magriotis、Stephen E. de Laszlo、Bing Li、Malcolm MacCoss、Usha Kidambi、Linda A. Egger、Ermengilda McCauley、Gail Van Riper、Richard A. Mumford、John A. Schmidt、William K. Hagmann

  DOI：10.1016/s0960-894x(02)00210-x

  日期：2002.6

  Given the proposed involvement of VLA-4 in inflammatory processes, a program to identify orally active VLA-4 antagonists was initiated. Herein, we report the discovery of a N-tetrahydrofuroyl-(L)-phenylalanine derivative (17) and related analogues as potent VLA-4 antagonists with good oral bioavailability. (C) 2002 Elsevier Science Ltd. All rights reserved.